Our study provides a theoretical foundation for the treatment of MF-based cardiovascular diseases, with TIMP1 as a potential therapeutic target for LC to promote cardiovascular health and prolong life expectancy in older individuals. Here, TIMP1 is linked to cardiovascular disorder.